Apeloa PharmaceuticalLtd Past Earnings Performance
Past criteria checks 2/6
Apeloa PharmaceuticalLtd has been growing earnings at an average annual rate of 12.2%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 12.1% per year. Apeloa PharmaceuticalLtd's return on equity is 16.3%, and it has net margins of 8.8%.
Key information
12.2%
Earnings growth rate
12.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 12.1% |
| Return on equity | 16.3% |
| Net Margin | 8.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Apeloa PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 12,264 | 1,074 | 1,101 | 608 |
| 30 Jun 24 | 11,948 | 1,079 | 1,143 | 588 |
| 31 Mar 24 | 11,587 | 1,060 | 1,135 | 576 |
| 31 Dec 23 | 11,474 | 1,055 | 1,127 | 625 |
| 30 Sep 23 | 11,494 | 1,183 | 1,034 | 612 |
| 30 Jun 23 | 11,514 | 1,153 | 1,005 | 602 |
| 31 Mar 23 | 11,529 | 1,076 | 1,048 | 593 |
| 01 Jan 23 | 10,545 | 989 | 998 | 533 |
| 30 Sep 22 | 10,094 | 851 | 970 | 530 |
| 30 Jun 22 | 9,651 | 839 | 965 | 523 |
| 31 Mar 22 | 9,077 | 890 | 906 | 491 |
| 01 Jan 22 | 8,943 | 956 | 925 | 446 |
| 30 Sep 21 | 8,468 | 949 | 973 | 399 |
| 30 Jun 21 | 8,165 | 941 | 964 | 369 |
| 31 Mar 21 | 8,146 | 879 | 986 | 362 |
| 31 Dec 20 | 7,880 | 817 | 967 | 350 |
| 30 Sep 20 | 7,606 | 752 | 1,074 | 356 |
| 30 Jun 20 | 7,653 | 702 | 1,169 | 383 |
| 31 Mar 20 | 7,236 | 598 | 1,241 | 373 |
| 31 Dec 19 | 7,211 | 553 | 1,293 | 360 |
| 30 Sep 19 | 7,122 | 529 | 1,332 | 344 |
| 30 Jun 19 | 6,855 | 465 | 1,328 | 299 |
| 31 Mar 19 | 6,605 | 414 | 1,324 | 273 |
| 31 Dec 18 | 6,376 | 371 | 1,279 | 270 |
| 30 Sep 18 | 6,246 | 367 | 1,198 | 279 |
| 30 Jun 18 | 5,882 | 313 | 1,015 | 392 |
| 31 Mar 18 | 5,674 | 275 | 1,000 | 328 |
| 31 Dec 17 | 5,552 | 257 | 1,000 | 259 |
| 30 Sep 17 | 5,313 | 253 | 986 | 182 |
| 30 Jun 17 | 5,312 | 279 | 1,088 | 0 |
| 31 Mar 17 | 5,112 | 274 | 1,031 | 0 |
| 31 Dec 16 | 4,772 | 263 | 977 | 0 |
| 30 Sep 16 | 4,476 | 201 | 914 | 0 |
| 30 Jun 16 | 4,349 | 190 | 910 | 0 |
| 31 Mar 16 | 4,284 | 198 | 877 | 0 |
| 31 Dec 15 | 4,338 | 208 | 861 | 0 |
| 30 Sep 15 | 4,195 | 231 | 823 | 0 |
| 30 Jun 15 | 4,219 | 236 | 768 | 0 |
| 31 Mar 15 | 4,281 | 241 | 743 | 0 |
| 31 Dec 14 | 4,233 | 322 | 719 | 0 |
| 30 Sep 14 | 4,112 | 313 | 697 | 0 |
| 30 Jun 14 | 4,100 | 305 | 671 | 0 |
| 31 Mar 14 | 3,991 | 274 | 641 | 0 |
| 31 Dec 13 | 3,855 | 167 | 608 | 0 |
Quality Earnings: 000739 has high quality earnings.
Growing Profit Margin: 000739's current net profit margins (8.8%) are lower than last year (10.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000739's earnings have grown by 12.2% per year over the past 5 years.
Accelerating Growth: 000739's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 000739 had negative earnings growth (-9.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 000739's Return on Equity (16.3%) is considered low.